Clinicoimmunological characteristics were followed up in the course of laryngeal papillomatosis (LP) in 96 children. It was found that they had suppressed T-cell immunity, phagocytosis which still worsen with the disease aggravation and recurrences. A decrease in nonspecific resistance, properdin, lysozyme, complement and secretory IgA indicated impairment of nasopharyngeal and laryngeal local immunity. A scheme of combined treatment is proposed incorporating basic therapy with reaferon, systemic immunomodulators (thymalin, T-activin) and local immunocorrection. Such approach reduced the time of basic treatment and prolonged remission 2.5-3-fold.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
"A systematic literature review of the epidemiology, clinical, economic and humanistic burden in recurrent respiratory papillomatosis".
Respir Res
December 2024
MSD, Puteaux, France.
Introduction: Recurrent respiratory papillomatosis (RRP) is a chronic disease caused by human papillomavirus (HPV), characterized by recurrent papillomas in the respiratory tract. Presenting as either juvenile-onset RRP (JoRRP) or adult-onset RRP (AoRRP), the severity of the disease is subjective and unpredictable. Lack of curative therapies necessitates disease management involving repeated surgical removal of lesions.
View Article and Find Full Text PDF[Laryngeal Papillomatosis In Niamey: Epidemiological, Diagnostic And Therapeutic Aspects].
Mali Med
November 2024
Service ORL-CCF de l'Hôpital Général de Référence de Niamey.
Objective: to present the epidemiological, diagnostic, therapeutic and progressive aspects of laryngeal papillomatosis.
Patients And Method: This was a retrospective study over a period of 6 years (January 2016 to December 2021), covering cases of laryngeal papillomatosis collected at the Oto-Rhino-Laryngology department of the Niamey National Hospital.
Results: A total of 36 cases of laryngeal papillomatosis were recorded.
[Overview of the ASCO 2024 data on head and neck surgery].
HNO
December 2024
Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie, Universitätsklinikum Würzburg, Josef-Schneider-Straße 11, 97080, Würzburg, Deutschland.
At the 2024 international cancer congress of the American Society of Clinical Oncology (ASCO), studies on immuno-oncological therapeutic approaches for head and neck cancers once again took center stage. Following the trend of recent years, neoadjuvant immunotherapy has now reached a central role, and purely surgical studies have become increasingly scarce. This review article summarizes abstracts presented at the 2024 ASCO Annual Meeting that focus on surgical therapy or in which surgery was a significant component of the study protocol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!